FoRx Therapeutics Presents Preclinical Data at ACS Spring 2026, Confirming FORX-428’s Potential for Best-in-Class PARG Inhibition

• PARG is a next-generation DDR target with significant potential in PARP inhibitor-resistant cancers 
• Preclinical data show high potency across multiple solid tumor cell lines and in vivo models, including those resistant to PARP inhibitors
• Presentation also includes molecular structure and discovery data
• Initial data from an open-label Phase 1 study of FORX-428 in patients with advanced solid tumors expected mid-2026

Basel, Switzerland – March 26, 2026 – FoRx Therapeutics, a clinical-stage biotechnology company developing precision anti-cancer therapeutics, today announced the presentation of the molecular structure, discovery, and preclinical data supporting the potential best-in-class profile of its PARG inhibitor, FORX-428, currently in Phase 1 development, at the American Chemical Society (ACS) Spring 2026 meeting in Atlanta.

This disclosure of the novel molecular structure of FORX-428 represents the first description of the discovery and chemical structure of a clinical-stage PARG inhibitor candidate.

Data presented at ACS Spring 2026 showed FORX-428’s differentiated preclinical profile relative to a competitor reference compound, including superior selectivity and pharmacokinetics (PK), with potency shown to be at least 10-fold higher across multiple solid tumor cell lines. FORX-428 has demonstrated the potential for a best-in-class profile, supported by favorable preclinical safety and toxicology data and a promising predicted human PK profile.

In preclinical studies, FORX-428 showed robust anti-tumor activity in hard-to-treat models across three distinct target populations: HRD-positive, PARP inhibitor-resistant, and high replication stress tumors. By comparison, the reference compound showed activity primarily in highly sensitive models.

Tarig Bashir, CEO of FoRx Therapeutics, said: “The robust preclinical data presented at ACS Spring 2026 support FORX-428’s best-in-class potential and why we believe it has the potential to meaningfully improve treatment options for patients. Our ongoing Phase 1 trial is progressing according to plan toward an initial clinical readout in the coming months.”

The discovery that distinct genetic subsets of cancer are exceptionally vulnerable to drugs that interfere with the DNA Damage Response (DDR) led to the approval of PARP inhibitors more than 10 years ago, transforming cancer treatment. FoRx is pursuing PARG as a next-generation DDR target with significant potential as a new treatment approach for patients whose cancers are resistant to, or have become resistant to, PARP inhibitors.

The Phase 1 trial of FORX-428 is progressing as planned, with initial data readout expected in mid-2026. The open-label study, which began recruitment in August 2025 and is being conducted at leading cancer centers in the United States, is evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors who have exhausted standard-of-care options.

ACS Spring 2026 is taking place in Atlanta, Georgia, USA, from March 22 to 26.

FoRx Therapeutics (Basel, Switzerland) is a privately held clinical-stage biotechnology company pioneering precision therapeutics targeting the DNA Damage Response in treatment-resistant cancers. Its lead product candidate FORX-428, an oral small molecule PARG inhibitor, is in Phase 1 testing to treat advanced solid tumors.

FORX-428 is designed to inhibit the poly (ADP-ribose) glycohydrolase (PARG) enzyme to cause tumor cell death. PARG is a key DNA repair enzyme necessary for the survival of certain genetically defined cancers, harboring specific DDR deficiencies or high replication stress. Preclinical studies demonstrated that FORX-428 has robust anti-tumor activity across multiple solid tumor types, underscoring the novel compound’s promising potential in both monotherapy and combination settings. Importantly, FORX-428 was well tolerated, demonstrating drug-like pharmacology and a favorable safety profile.

http://www.forxtherapeutics.com/

For more information, please contact:

Attachment

• 20260326 FoRx ACS Compound Final